AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 212 min read$ABT

Abbott Plans to Spin Off Its Nutrition Business

Abbott plans to spin off its nutrition business, which generates $8.5bn in annual revenue, into an independent publicly traded company by the end of 2027. The move aims to allow both entities to focus on their respective markets. Abbott's remaining business will have $42bn in revenue and focus on medical devices, diagnostics, and pharmaceuticals. The transaction is subject to regulatory approvals and will not impact Abbott's 2026 and 2027 guidance.

Original reporting
marketscreener.com
Published Oct 21, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ABT
Neutral
high confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ABTNeutralMed
01

Why it matters

The announced spin‑off creates a standalone nutrition company, distributing shares to existing Abbott shareholders, and is expected to be completed by end‑2027.

02

Market read

A major corporate restructuring that could reshape Abbott's valuation and create a new listed nutrition player.

03

What to watch

Regulatory approvals and timing delays could postpone value realization; the new entity may face competitive pressures in the nutrition space.

Relevance 7/10Novelty 8/10Timing: immediate – news released today

Background

Abbott Laboratories (ABT) is a diversified health‑care company with major businesses in medical devices, diagnostics, and pharmaceuticals. The nutrition segment accounts for ~19% of sales.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott announced a plan to spin off its nutrition business into a separate publicly traded company, creating a new entity with ~$8.5 bn revenue.

Expected impact

possible modest pressure on ABT as investors assess the split, with upside potential if the nutrition spin‑off is valued favorably.

Evidence & confidence

Spin‑offs are material corporate actions; the disclosed revenue size and timeline are new information, allowing traders to position ahead of the separation.

Market effects

Sector

Nutrition segment may become a pure‑play health‑nutrition stock, affecting peer comparisons in consumer health and specialty nutrition sectors.

Regional

Abbott's global footprint means the spin‑off could attract interest from investors focused on emerging‑market nutrition demand.

Global

Large‑cap spin‑off with $8.5 bn revenue is noteworthy for global equity markets and may influence index weightings.

Counterpoint

What could challenge this read

The spin‑off could dilute Abbott's earnings visibility and increase execution risk, potentially weighing on ABT if integration costs rise.

Key entities

  • Company
    Abbott Laboratories

    US‑listed health‑care conglomerate planning the spin‑off.

  • Executive
    Robert B. Ford

    CEO of Abbott who announced the separation.

Read at source← All news

StoryAbbott to spin off Nutrition business into independent public company

Also covered by

6 outlets

Related articles

OCT 21
$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

finance.yahoo.com2 min
OCT 21
$ABTHighAI 8/10

Abbott Laboratories Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Abbott Laboratories reported Q3 2026 sales of $13.01B (up from $11.37B YoY) and net income of $920M (down from $1.64B YoY). Nine-month sales reached $36.77B (up from $32.87B YoY), with net income of $2.93B (down from $4.75B YoY). The company's products include vascular devices, diagnostic systems, nutrition products, and medicines, with sales distributed globally.

marketscreener.com2 min
OCT 21
$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

SEC EDGAR 8-K3 min
OCT 21
$ABTMed

Abbott Laboratories (ABT) Plans Nutrition Spin-Off Amid Dividend

Abbott Laboratories (ABT) plans to spin off its Nutrition division, including brands like Similac, by the end of 2027. The move aims to unlock shareholder value, with the new entity to be led by Daniel Salvadori. Abbott's shares trade at a 24.5% discount to its GF Value of $135.69, offering a 2.59% dividend yield with a high payout ratio of 80%. The company reported better-than-expected Q3 2026 results but saw a slight share price dip post-announcement.

gurufocus.com3 min
OCT 21
$ABTHighAI 8/10

Abbott slips after cutting 2026 growth outlook amid nutrition spinoff

Abbott Laboratories ABT reported Q3 2026 revenue of $13.0B, up 14.5% YoY, beating estimates. However, it lowered its 2026 growth outlook due to a planned nutrition business spinoff. Nutrition and Diagnostics units performed well, while MedTech and Pharma segments underperformed. Adjusted EPS rose 9% YoY to $1.42, exceeding forecasts.

tradingview.com2 min